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Materials andmethods: Respondents from67 hospitals participating in The Collaborative European NeuroTrauma
Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study completed several questionnaires onman-Purpose:Weaimed to study variation regarding specific end-of-life (EoL) practices in the intensive care unit (ICU)
agement of TBI patients.
Results: In 60% of the centers, ≤50% of all patients with severe neurological damage dying in the ICU, die after
withdrawal of life-sustaining measures (LSM). The decision to withhold/withdraw LSM was made following
multidisciplinary consensus in every center. Legal representatives/relatives played a role in the decision-
making process in 81% of the centers. In 82% of the centers, age played a role in the decision to withhold/with-
draw LSM. Furthermore, palliative therapy was initiated in 79% of the centers after the decision to withdraw
LSM was made. Last, withholding/withdrawing LSM was, generally, more often considered after more time
had passed, in a patient with TBI, who remained in a very poor prognostic condition.
Conclusion:We found variation regarding EoL practices in TBI patients. These results provide insight into variabil-
ity regarding important issues pertaining to EoL practices in TBI, which can be useful to stimulate discussions on
EoL practices, comparative effectiveness research, and, ultimately, development of recommendations.
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Life-sustaining measures (LSM), such as mechanical ventilation,
have allowed physicians to prolong the life of patients. However, these
LSMmay sometimes be considered as disproportionatewhen they post-
pone unavoidable death and, as a consequence, may only result in
prolonged suffering of patients and their relatives. Therefore, in many
countries, it is seen as good medical practice to withhold or withdraw
LSM in these situations and allow the patient to die when further treat-
ment is judged as disproportionate [1,2].
A systematic review reported variation in the prevalence of with-
drawing/withholding LSM [3] resulting from institutional factors [4–
10], physician factors [10–14], and religion/geographic factors [14–16].
Recent studies have advised to also study variation pertaining to specificer the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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practices is understandable, given the complexities of EoL care. How-
ever, if considerable variation negatively influences patient care, this
variation may not be acceptable. One driving issue here is that with-
drawal of LSM may be inappropriately instituted in individuals who
have a chance of good quality survival. Furthermore, important issues
may be that symptom control duringwithdrawal is suboptimal, interac-
tions with families may be compromised, ethical issues may not be ap-
propriately addressed, and organ donation may be affected. Studying
variation may provide insight into these issues in patients with trau-
matic brain injury (TBI) on the intensive care unit (ICU), which can be
useful to stimulate discussions regarding EoL best practices, and, ulti-
mately, development of recommendations [3,17]. Furthermore, varia-
tion may inform comparative effectiveness research (CER), which
entails studying the impact of differences in patient management on
outcomes to inform best practices.
Therefore, we aimed to study variation regarding specific EoL prac-
tices in TBI patients. We investigated the occurrence of withdrawing
LSM, how the decision to withhold/withdraw LSM was made, the role
of legal representatives/relatives, if age influenced the decision-
making process, the initiation of palliative therapy, and the timing and
execution of withholding/withdrawing LSM.
2. Methods
2.1. CENTER-TBI and study sample
The Collaborative European NeuroTrauma Effectiveness Research in
Traumatic Brain Injury (CENTER-TBI,www.center-tbi.eu) study is a pro-
spective observational study on traumatic brain injury (TBI) [18,19]. For
this, data on patient characteristics, management and outcomes
were collected in centers from 20 countries across Europe and
Israel (Fig. 1). Further, respondents from all participating centers
in the CENTER-TBI study were asked to complete questionnaires
which were used to create “provider profiles” of participating
neurotrauma centers [20].
2.2. Questionnaire development and administration
The topics investigated for this provider profile study, are summa-
rized in Table 1. In the questionnaires, we explicitly asked respondents
to provide their understanding of the “general policy” for their institu-
tion.Wedefined this as the local standards used inmore than 75% of pa-
tients, recognizing that there might be exceptions. Most questions used
categorical answers. For some questions, the respondents had the op-
tion to fill in “other” and provide a free text response.
In an earlier publication from Cnossen et al. [20], detailed informa-
tion about the development, administration, and content of the ques-
tionnaires is available.
2.3. Analyses
We calculated frequencies and percentages for all questions. The
sample total of question two and six could exceed 100% because the re-
spondents had the option to providemore than one response. For ques-
tion six, we made a new response category. The result of this response
category is the sum of centers that filled in all response categories for
that question. Furthermore, for question seven, respondents could an-
swer “never”, “sometimes”, “often”, or always”. For the analyseswe con-
sidered “never” and “sometimes” as “no general policy”, and “often” and
“always” as “general policy”. Question five had six answers, of which
four had a similar meaning. We combined these four answers to define
one response category (Table 1).
We examined potential variation between and within seven regions
based on the United Nations geo-scheme: Baltic States (Latvia, and
Lithuania), Eastern Europe (Bosnia and Herzegovina, Hungary,Romania, and Serbia), Israel, Northern Europe (Denmark, Finland,
Norway, and Sweden), Southern Europe (Italy, and Spain), the United
Kingdom, and Western Europe (Austria, Belgium, France, Germany,
the Netherlands, and Switzerland).
3. Results
3.1. Center characteristics
Of the 68 centers, 67 filled in the questionnaires and were included
in the analysis. Between questions the response rate varied from 96 to
99%. Most participating centers were academic centers (N= 61, 91%),
designated as a level I or II trauma center (N = 49, 73%). The average
number of beds was 1187 of which on average 39 were ICU beds. In
2013, the median annual number of TBI patients was 92 (interquartile
range (IQR) 53–159). The questionnaire about ethical aspects of the
ICU was mostly completed by intensivists, neurosurgeons, and
neurologists.
Of all patients with severe neurological damage who die in the
ICU, approximately, how many die after withdrawal of life-
sustaining measures?
In 60% of the centers, ≤50% of all patients with severe neurological
damage who die in the ICU, died after withdrawal of LSM. In 40% of
the centers, this was N50%. In 56% of the centers from Northern
Europe, N75% of the patients with severe neurological damage who
die in the ICU, died after withdrawing LSM. Contrary, in most centers
from the Baltic States, Israel, and Southern Europe (80%, 100%, and
75% respectively), this was b25% (Fig. 2).
How is the decision reached to withhold/withdraw life-
sustaining measures (e.g. mechanical ventilation, vasoactive medi-
cation, renal replacement therapy, intravenous fluid
administration)?
In 67% of the centers, multidisciplinary discussion following consen-
sus among all participating physicians was preferred. This was also pre-
ferred in most centers in Southern Europe, the United Kingdom (UK)
and Western Europe (75%, 75%, and 84% respectively). In Northern
European centers, however, this was preferred in 33% of the centers
(Table 2).
Does the age of the patient influence your decisionmaking about
withholding and withdrawing life-sustaining treatment?
In 81% of the centers, age influenced the decision-making process,
together with other criteria. This was also the case in all centers in
Southern Europe. However, in the Baltic States and Eastern Europe,
age did not play a role in 60%, and 50% of the centers respectively
(Table 2).
Towhat extent do opinionsof legal representatives/relatives play
a role in decision-making about withdrawal/withholding of life-
sustaining measures?
In 19% of the centers, legal representatives/relatives playedno role in
the decision-making process before withholding/withdrawing LSM.
This was the case in 67% of the centers in Northern Europe. Contrary,
in all centers in Israel, and in 60% of the centers in Western Europe,
legal representatives/relatives played a role in the decision-making pro-
cess to some or to a great extent (Fig. 3).
If the decision is made to withdraw life-sustainingmeasures and
before actual withdrawal, do you initiate palliative therapy in antic-
ipation of distressing symptoms (such as pain, terminal restlessness,
death rattle, stridor, dyspnoea)?
In 79% of the centers, palliative therapy in anticipation of distressing
symptoms after the decision to withhold/withdraw LSM was initiated.
In Northern Europe, Southern Europe, and Western Europe this was
the case in 78%, 92%, and 96% respectively. Contrary, in 60% of the cen-
ters from the Baltic States, palliative therapy was not initiated (Fig. 4).
If the decision is made to withdraw life-sustainingmeasures in a
comatose severely injured TBI patent, which life-sustaining mea-
sures do you stop?
Fig. 1. Number of hospitals.
Table 1
Topics covered in this study, and the related questions to each topic.
Occurrence of withdrawing LSM
1. Of all patients with severe neurological damage who die in the ICU,
approximately, how many die after withdrawal of life-sustaining
measures?
Practices around the decision-making process
2. How is the decision reached to withhold/withdraw life-sustaining mea-
sures (e.g. mechanical ventilation, vasoactive medication, renal replace-
ment therapy, intravenous fluid administration)?
3. To what extent do opinions of legal representatives/relatives play a role in
decision-making about withdrawal/withholding of life-sustaining
measures?
4. Does the age of the patient influence your decision making about with-
holding and withdrawing life sustaining treatment?
Practices before withholding/withdrawing LSM
5. If the decision is made to withdraw life-sustaining measures and before
actual withdrawal, do you initiate palliative therapy in anticipation of
distressing symptoms (such as pain, terminal restlessness, death rattle,
stridor, dyspnoea)?
Timing and execution of withholding/withdrawing LSM
6. If the decision is made to withdraw life-sustaining measures in a comatose
severely injured TBI patent, which life-sustaining measures do you stop?
7. At what time after injury would you consider to withdraw life support in a
patient with TBI, who is in a very poor prognostic condition (based on CT
scan, GCS, clinic, ICP etc), but not brain dead?
Abbreviations: CT: Computed Tomography, GCS: Glasgow Coma Scale, ICP: Intracranial
Pressure, ICU: Intensive Care Unit, LSM: Life-sustaining measures, TBI: Traumatic brain
injury.
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would be stopped in 63% of the centers, the administration of vasoactive
medication would be stopped in 93% of the centers, renal replacement
therapy would be stopped in 81% of the centers, the administration of
intravenous fluidswould be stopped in 34% of the centers, and nasogas-
tric feeding would be stopped in 58% of the centers. In 25% of the cen-
ters, all of these LSM would be stopped after the decision to withdraw
LSM (Table 3).
At what time after injury would you consider to withdraw life
support in a patient with TBI, who is in a very poor prognostic con-
dition (based on CT scan, GCS, clinic, ICP etc), but not brain dead?
In general, there was an increase in considering withholding/with-
drawing LSM after more time had passed (ranging from 24 h to
N2weeks), in a patientwith TBI, whowas in a very poor prognostic con-
dition but not brain dead. In 25% of the centers from Southern Europe,
and in 16% of the centers fromWestern Europe, withholding/withdraw-
ing LSM would be considered after 24 h. In 40% of the centers from the
Baltic States, and in 25% of the centers from the UK this was considered
after N2 weeks (Table 3).
4. Discussion
We aimed to study the variation regarding specific end-of-life (EoL)
practices in critically ill traumatic brain injury (TBI) patients, using
questionnaires filled in by experts in participating neurotrauma centers.
We found variation in the occurrence of withdrawing LSM, how the de-
cision to withhold/withdraw LSMwas made, the role of legal represen-
tatives/relatives, the influence of age in the decision-making process,
the initiation of palliative therapy, and the timing and execution of
Fig. 2. Of all patients with severe neurological damage who die on the intensive care unit, approximately, how many die after withdrawal of life-sustaining measures?
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variation regarding EoL practices in TBI,which can beuseful to stimulate
discussions on EoL practices, comparative effectiveness research (CER),
and recommendations.
First, we found variation in the occurrence of withdrawing LSM. This
is in line with previous literature [3], showing not only variation within
countries [4–6,10,21–27], but also within departments [12].
Second, we found variation regarding the decision-making process.
All centers responded that they preferred multidisciplinary discussion
beforewithdrawing/withholding LSM. This is in linewith recommenda-
tions in previous literature [28–30]. However, the way this multidisci-
plinary discussion was implemented varied across centers. We also
found variation regarding the extent of the role of legal representa-
tives/relatives in this decision-making process. Previous literatureTable 2
Practices around the decision-making process regarding withholding/withdrawing LSM.
Sample
total
(N = 67)
Baltic
States
(N = 5)
How is the decision reached to withhold/withdraw life-sustaining measures (e.g. mechan
therapy, intravenous fluid administration)?
One physician (e.g. the most senior person) decides following
multidisciplinary discussion
10 (15%) 1 (20%)
During multidisciplinary discussion in which the majority
(more than 50%) has to agree
14 (21%) 1 (20%)
During multidisciplinary discussion in which there has to be
unanimous consensus among all participating doctors
45 (67%) 2(40%)
One physician decides (along with objective medical criteria)
without multidisciplinarydiscussion (veto)
0(0%) 0(0%)
Othera 2(3%) 1(20%)
Does the age of the patient influence your decision making about withholding and withdr
Yes, always, independent of other criteria 1(1%) 0(0%)
Yes, but only in combination with other criteria as CT scan, GCS,
depth of coma
54(82%) 2(40%)
No, I only decide on the severity of the injury and anticipated
prognosis
12(18%) 3(60%)
Abbreviations: CT: Computed Tomography, GCS: Glasgow Coma Scale, LSM: Life-sustaining mestressed the importance of legal representatives/relatives in the
decision-making process [29–31]. A Canadian questionnaire study
showed that 39% of surrogate decision-makers wanted to share respon-
sibility for the decision [32]. However, Wendler and Rid found that at
least one third of the surrogate decision-makers could be emotionally
burdened after making treatment decisions for incapacitated loved
ones [33]. Healthcare providers should contemplate on whether or not
they wish to communicate the uncertainty involved in EoL decision-
making (when such prognostic uncertainty is indeed present), because
it might have unpredictable impact on this emotional burden of legal
representatives/relatives. Reasons to communicate about uncertainty
have already been raised by Smith et al. and Lazaridis [34,35]. Smith
et al. proposed a framework that should be adapted to the core values
of the patient [34]. By following this framework, legal representatives/Eastern
Europe
(N = 6)
Israel
(N = 2)
Northern
Europe
(N = 9)
Southern
Europe
(N = 12)
United
Kingdom
(N = 8)
Western
Europe
(N = 25)
ical ventilation, vasoactive medication, renal replacement
0(0%) 2
(100%)
3(33%) 0(0%) 2(25%) 2(8%)
2(33%) 1(50%) 3(33%) 3(25%) 0(0%) 4(16%
4(67%) 0(0%) 3(33%) 9(75%) 6(75%) 21(84%)
0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%)
0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 1(4%)
awing treatment?
0(0%) 1(50%) 0(0%) 0(0%) 0(0%) 0(0%)
3(50%) 1(50%) 7(78%) 12(100%) 6(75%) 23(92%)
3(50%) 0(0%) 2(22%) 0(0%) 2(25%) 2(8%)
asures.
Fig. 3. To what extent do opinions of legal representatives/relatives play a role in decision-making about withdrawal/withholding of life-sustaining measures?
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decisions. A multisociety statement recommended that the medical
profession should lead public engagement efforts and advocate policies
and legislation about the use of life-prolonging technologies [36]. These
policies and legislation could be informative for the decision to involve
legal representatives/relatives in the decision-making process.
Third, we found variation in practices before withholding/with-
drawing LSM. Decisions regarding palliative therapy were not formal-
ized in a protocol in the majority of centers. Despite this, palliative
therapy was initiated in most centers after the decision to withhold/
withdraw LSM. Where such care was not reported, the response
might have been influenced by the wording of our questionnaire,
which may have been construed as starting such therapy in advanceFig. 4. If the decision is made to withdraw life-sustaining measures and before actual withdraw
terminal restlessness, death rattle, stridor, dyspnoea)?of, rather than at the time of, withdrawing LSM. Palliative therapy
might be common practice in general, but not in anticipation of
distressing symptoms. Past recommendations stressed the importance
of good palliative care [29,30,37]. Previous literature described that
there should be no maximum dosage of narcotics or sedatives [30,37].
The right amount of drugs should be adapted to the need of the individ-
ual patient. Furthermore, Hawryluck et al. described, that pre-emptive
dosing in anticipation of pain and suffering should be considered as
good palliative care if the intent of the physician is clear and well docu-
mented [37].
Fourth,we found variation regardingwhich LSM to stop after the de-
cision to withhold/withdraw LSM was made. In a quarter of centers, all
LSM were stopped after the decision to withhold/withdraw LSM.al, do you initiate palliative therapy in anticipation of distressing symptoms (such as pain,
Table 3
Timing and execution of withholding/withdrawing life-sustaining measures (LSM).
Sample
total
(N = 67)
Baltic
States
(N = 5)
Eastern
Europe
(N = 6)
Israel
(N = 2)
Northern
Europe
(N = 9)
Southern
Europe
(N = 12)
United
Kingdom
(N = 8)
Western
Europe
(N = 25)
If the decision is made to withdraw life-sustaining measures in a comatose severely injured TBI patient, which life-sustaining measures do you stop?
We stop mechanical ventilation 42
(63%)
4
(80%)
1
(17%)
0
(0%)
8
(89%)
3
(25%)
8
(100%)
18
(72%)
We stop administration of vasoactive medication 62
(93%)
5
(100%)
4
(67%)
2
(100%)
8
(89%)
10
(83%)
8
(100%)
25
(100%)
We stop renal replacement therapy 54
(81%)
4
(80%)
1
(17%)
2
(100%)
8
(89%)
9
(75%)
7
(88%)
23
(92%)
We stop administration of intravenous fluids 23
(34%)
3
(60%)
1
(17%)
1
(50%)
4
(44%)
1
(8%)
2
(25%)
11
(44%)
We stop nasogastric feeding 39
(58%)
3
(60%)
2
(33%)
1
(50%)
8
(89%)
5
(42%)
3
(38%)
17
(68%)
Number of centers that indicated to stop all of the above
life-sustaining measures
17
(25%)
3
(60%)
0
(0%)
0
(0%)
4
(44%)
0
(0%)
1
(13%)
9
(36%)
At what time after injury would you consider to withdraw life support in a patient with TBI, who is in a very poor prognostic condition (based on CT scan, GCS, clinic, ICP etc),
but not brain dead? a
24 h 7
(10%)
0
(0%)
0
(0%)
0
(0%)
0
(0%)
3
(25%)
0
(0%)
4
(16%)
2–4 days 13
(19%)
0
(0%)
0
(0%)
0
(0%)
2
(22%)
4
(33%)
1
(13%)
6
(24%)
4–7 days 18
(27%)
0
(0%)
1
(17%)
0
(0%)
4
(44%)
5
(42%)
2
(25%)
6
(24%)
N1 week 25
(37%)
0
(0%)
0
(0%)
1
(50%)
5
(56%)
7
(58%)
1
(13%)
11
(44%)
N2 weeks 30
(45%)
2
(40%)
0
(0%)
1
(50%)
5
(56%)
5
(42%)
2
(25%)
15
(60%)
Abbreviations: CT: Computed Tomography, GCS: Glasgow Coma Scale, ICP: Intracranial Pressure, LSM: Life-sustaining measures, TBI: Traumatic brain injury.
83E. van Veen et al. / Journal of Critical Care 58 (2020) 78–88Previous literature suggested to critically evaluate all LSM that provide
no comfort to dying patients, for whom the chances for meaningful re-
covery are absent. [28,30]. Asch et al. reported that blood products and
hemodialysis, were among the LSMmost preferablywithdrawn by phy-
sicians, while tube feeding and intravenous fluids were least preferred
to be withdrawn [38]. This is in line with our results. One reason for
the reluctance to withdraw tube feeding and intravenous fluids could
be that physicians believe that this could be perceived as starving the
patient. On the other hand, continuing feeding and fluids might also
prolong suffering at the end-of-life because the patient my live longer
due to this “active” treatment.
Last, we foundvariation inwhenwithdrawal of LSMwas considered,
and how often age influenced the decision-making process of with-
drawing LSM. A previous study found that brain injury was an impor-
tant trigger for withdrawing LSM [39]. Our results show that
withdrawing LSM in a patient with very poor prognostic conditions
but who is not brain dead was considered after 4–7 days in more than
a quarter of the centers, and that age was a criterion for the decision
to withdraw life-sustaining measures in many centers. Obviously,
there is a general tendency to practice the “benefit of the doubt” in
poor grade patients early in the course. The use of “considered” in our
question meant that we could not be sure of the frequency with
which such consideration actually led to the withdrawal of LSM. Conse-
quently, caution is needed in interpreting the responses to this question.
In general, physicians should exercise extreme caution regarding early
prognostication and withdrawal of LSM following severe traumatic
brain injury in spite of the existence of validated prognostic models
[40,41]. Based on our results, in Northern European centers, patients
in the intensive care unit (ICU) with severe neurological damage may
have died more frequently because of withdrawal of LSM compared to
other regions. Thisfinding could lead to one of two diametrically oppos-
ing inferences. On onehand, the practice in Northern Europemaybe ap-
propriate, and ensure that patients who have no prospect of an
acceptable functional outcome have withdrawal of LSM, thus minimiz-
ing the burden of suffering to the patient and family, and optimizing
the use of limited health care resources. On the other hand, given thatthere was less unanimous consensus needed for the decision to with-
draw LSM in Northern European countries, this practice could indicate
a potential for self-fulfilling prophecies [42]. Self-fulfilling prophecies
may exist in TBI too [43]. Early withholding/withdrawing of LSM, and
withholding of treatment of patients that are “too old”, could lead to
those self-fulfilling prophecies. On the Durban World Congress, ethics
experts concluded that age should not be the sole criterion upon
which to decide towithhold/withdraw LSM [44]. Although age is an im-
portant factor in prognostic models in TBI [40,41], and even though in-
creasing age has been found to be independently associated with the
decision to withdraw LSM [6,45], clinicians should be cautious taking
age as a dominant criterion to withdraw LSM. Regarding the timing of
withdrawing LSM, in a position statement from the Neurocritical Care
Society, the recommendationwas towait at least 72 h beforewithdraw-
ing LSM in patients with devastating brain injury [29]. “Early” with-
drawal of LSM might be unwise due to too much uncertainty of the
prognosis. On the other hand, “late” withdrawal of LSM would not al-
ways be in the best interest of the patient because of the potential for
prolonged suffering. Finding the balance between resolving prognostic
uncertainty and preventing harm and suffering in individual patients
remains a difficult and incompletely resolved clinical problem.
Our study has limitations that should be considered when
interpreting the results. First, our results are based on the perceptions
of practices reported by respondents rather than actual clinical practice
data. However, even if this is the case, the fact that respondents' an-
swers vary between centers, already provides insight in variation across
European and Israeli neurotrauma centers. Second, some of our ques-
tions were open to ambiguity and may not have been interpreted cor-
rectly by the respondents. For example, in the questionnaire, we made
no distinction between withholding and withdrawing life-sustaining
measures. Because clinical choices could be different between the two,
thismay have influenced the results. In any case, a questionnaire cannot
capture all the nuances that underpin clinical practice, which involves
many complex potential alternative options that cannot be captured
by questionnaires. Third, our results should invoke discussions rather
than be considered as definitive, given the nature and room for
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not be representative for all neurotrauma centers within the geograph-
ical areas studied, because the participating neurotrauma centers repre-
sent a select group. Fifth, the results come from data obtained in 2013.
Last, it is possible that amore favorable picture or individual preferences
may have been presented (even unwittingly), instead of the general
policy in a center.
Medical practices are affected by the cultural climate of the society in
which they exist [46]. Therefore, culture may explain some of the ob-
served variation, such as the lack of influence of legal representatives/
relatives in the decision-making process. Other variation, such as the
possibility to withdraw LSM may have a more legal basis. For example,
in Israel withdrawing mechanical ventilation is against the law [47].
However, most variation found in our study also appears to be within
regions, and even within the countries in those regions. Thus, on the
basis of our results, we cannot clearly attribute the variation to specific
region or country characteristics such as most prevalent religion.
Our data comes from diverse sources, representing many cultural,
religious and legal backgrounds. Our intent is not to change the daily
practices of clinicians but to provide insight into systems used in other
countries with a view to establishing common ground. Furthermore,
withdrawing LSM should not preempt the availability and affordability
of palliative care. Future research should study reasons for the found
variation (e.g. cultural differences, and differences pertaining to legisla-
tion). Moreover, future research should evaluate the effect of the varia-
tion of specific EoL practices on clinically relevant outcomes using
comparative effectiveness research. Such research should incorporate
bothmortality and long-term functional outcome to be able to interpret
the outcome data. The complexity of some of the drivers of reported
practicemakes the case for mixedmethods approaches to this problem,
with a potentially substantive role for qualitative research methods.
These strategies are important in order to inform preferred approaches
to improve the quality of care for patients and relatives, and to prevent
self-fulfilling prophecies.
Some variation between regions might always remain because of
differences in patients, physician preferences and experience, and insti-
tutional factors. A recent study showed that this variation is primarily
caused by differences between providers [48]. However, the
WELPICUS study, published in 2014 [49] showed that theoretical con-
sensus regarding EoL practices can be established. In order to put this
theoretical consensus into practice, recommendations for specific EoL
practices should be developed. The development of such recommenda-
tions can be facilitated through insight regarding important variations
in practice, further discussion, and CER. Where possible, multidisciplin-
ary and (inter)national groups should be involved in this development,
as should patient representatives, as this may promote acceptance of
recommendations on a broader scale.
5. Conclusion
We found variation regarding EoL practices in critically ill TBI pa-
tients, using questionnaires filled in by experts in European and Israeli
neurotrauma centers. Specific issues that vary and need to be consid-
ered in discussions on EoL practices, CER, and recommendations, are
the influence of legal representatives/relatives, the role of age in the
decision-making process, what LSM to withdraw/withhold, and the
timing of withdrawing/withholding LSM. Our results may give impetus
to the design of (prospective) studies on EoL practices, exploring the
role of self-fulfilling prophecies, further updating prediction models
on prognosis and optimizing palliative care.
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